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Benjamin Allubha2, Kate Chidzalo2,3, Duolao Wang4, Queen Dube5, Macpherson Mallewa5, 
Angela Allen6, Robert H. J. Bandsma3,7,8,9, Wieger P. Voskuijl1,2,3 & Stephen J. Allen4
Intestinal pathology in children with complicated severe acute malnutrition (SAM) persists 
despite standard management. Given the similarity with intestinal pathology in non-IgE mediated 
gastrointestinal food allergy and Crohn’s disease, we tested whether therapeutic feeds effective in 
treating these conditions may benefit children with complicated SAM. After initial clinical stabilisation, 
95 children aged 6–23 months admitted at Queen Elizabeth Central Hospital, Blantyre, Malawi between 
January 1st and December 31st, 2016 were allocated randomly to either standard feeds, an elemental 
feed or a polymeric feed for 14 days. Change in faecal calprotectin as a marker of intestinal inflammation 
and the primary outcome was similar in each arm: elemental vs. standard 4.1 μg/mg stool/day (95% 
CI, −29.9, 38.15; P = 0.81) and polymeric vs. standard 10 (−23.96, 43.91; P = 0.56). Biomarkers of 
intestinal and systemic inflammation and mucosal integrity were highly abnormal in most children 
at baseline and abnormal values persisted in all three arms. The enteropathy in complicated SAM did 
not respond to either standard feeds or alternative therapeutic feeds administered for up to 14 days. A 
better understanding of the pathogenesis of the gut pathology in complicated SAM is an urgent priority 
to inform the development of improved therapeutic interventions.
In 2016, severe wasting (weight-for-height Z score (WHZ) <−3) occurred in 17 million under-fives (2.5% of all 
children) and was estimated to account for between 7.4–7.8% of all child deaths1–3. A small percentage of children 
with severe acute malnutrition (SAM) require in-patient care because of poor feeding, medical complications 
such as severe oedema and infection, or failure to improve under community management4. Despite following a 
well-established World Health Organization (WHO) protocol4, case fatality in complicated SAM remains up to 
35%5–9 with additional deaths after hospital discharge8,10.
Intestinal pathology in SAM is thought to result from increased exposure to microbial pathogens and poor 
nutrition11–15. Small intestinal biopsy studies in SAM revealed Th-1 dominated intestinal inflammation with 
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variable degrees of villous atrophy, crypt hyperplasia and increased inflammatory infiltrate11,16–21. A recent biopsy 
and biomarker study in Zambian children with SAM and persistent diarrhoea not responding to standard therapy 
reported severe enteropathy with intestinal barrier failure and immune dysregulation14. These histological and 
immune features are similar to those that occur in children with Crohn’s disease22 and also non-IgE-mediated 
gastrointestinal food allergies (hereafter “food allergy”; e.g. due to cow’s milk protein) although the pathology 
of these latter disorders is poorly understood20,21. The similarities in the intestinal pathology in these conditions 
raises the intriguing possibility that treatments that reduce gut inflammation in Crohn’s disease and food allergy 
may also be of benefit in SAM and formed the rationale for evaluating the alternative therapeutic feeds in this 
study.
Intestinal inflammation in food allergy responds well to exclusion of the offending dietary antigen or, if the 
offending antigen is not known, a hypoallergenic, elemental feed composed of single amino acids23. In paediatric 
Crohn’s disease, first-line therapy is with exclusive enteral nutrition where all foods are replaced by an elemental 
formula or polymeric formula22–25. In limited previous research, hypoallergenic and elemental feeds were well 
tolerated in children with malnutrition and associated with improved weight gain26,27. However, assessment of 
impact in these studies was limited to nutritional recovery and did not assess effects on intestinal inflammation 
and other biomarkers of gut health. Also, recruitment in one study was limited to children who also had persistent 
diarrhoea26.
The concentration of calprotectin in faeces, a non-specific biomarker of intestinal inflammation, is validated in 
the diagnosis and management of inflammatory bowel disease28. Faecal calprotectin (FC) is markedly increased 
in SAM and remains elevated despite standard WHO management12,19.
Our hypothesis was that a hypoallergenic and an anti-inflammatory therapeutic formula would improve 
enteropathy and be well tolerated and safe in children with complicated SAM. The primary outcome was change 
in FC concentration. We also assessed biomarkers of intestinal integrity and systemic inflammation, tolerability 
of feeds, clinical outcomes and serious adverse events. Children managed with therapeutic feeds recommended 
by WHO formed the comparison group.
Methods
Study design. This randomised, open-label, 3-arm study was conducted at “Moyo” Nutritional Rehabilitation 
Unit, Queen Elizabeth Central Hospital, Blantyre, Malawi in accordance with the principles of good clinical prac-
tice and the Declaration of Helsinki29. The College of Medicine Research and Ethics Committee, Blantyre, Malawi 
(P.06/15/1745) and the Liverpool School of Tropical Medicine Ethics Committee, Liverpool, UK (15.048) gave 
approval.
Participant recruitment. Children admitted from January 1st to December 31st, 2016 were screened for 
eligibility. Inclusion criteria were age 6–23 months, SAM (WHZ <−3 and/or mid-upper arm circumference 
(MUAC) <11.5 cms and/or nutritional oedema)30; completed the stabilisation phase of management (assessed by 
their usual clinician to be clinically stable and tolerating F75 therapeutic feeds)4 and willing to stay on the ward 
for 2 weeks. We excluded children with a specific identifiable cause of malnutrition (e.g. feeding difficulties due to 
cerebral palsy; treatment for tuberculosis), those participating in another study or those with a sibling admitted 
with SAM. Both HIV positive and negative children were included. HIV positive children were already receiving 
ART before admission and this was continued during their care. Children were managed according to WHO 
guidelines using F75 therapeutic feeds during the stabilisation phase4.
Legal guardians were provided with verbal and written information either in Chichewa or English by a mem-
ber of the study team. Following witnessed signed or thumbprint informed consent, research staff allocated chil-
dren according to a computer-generated random sequence with blocks of random size in equal numbers to the 
three study arms. The legal guardian opened the next in a series of sealed, opaque envelopes each labelled with 
a unique study number and containing a coloured card indicating the intervention arm. Legal guardians were 
offered travel expenses.
Interventions. Children were allocated to standard feeds (ready-to-use therapeutic food (RUTF) or, if not 
tolerated, F100), polymeric feed (Modulen IBD; Nestlé Health Science; York, UK) or elemental feed (PurAmino; 
Mead Johnson Nutrition; Chicago, 606 USA). Nutriset CMV (Complex of Minerals and Vitamins) (Malaunay, 
France) was added to both of the alternative feeds to approximate the nutrient content of F-100 (Supplementary 
Table S1). All feeds were introduced gradually over 2–3 days and provided 3-hourly for 14 days. Mothers were 
encouraged to re-establish or continue breastfeeding. No feeds other than breastfeeding and the intervention 
formulas were administered. Care was according to standard Malawian practice based on WHO guidelines which 
included a malaria slide, blood count and an HIV rapid antibody test, chloramphenicol and gentamicin as first 
line and ceftriaxone as second line antibiotic therapy and withholding oral iron until discharge4. All children 
received standard feeds after 14 days.
Clinical data and biological sample collection. Demographic, anthropometric, socioeconomic and 
clinical information was collected at recruitment. Children were reviewed daily by the research team and volume 
of feed taken, symptoms reported by parents/caregivers, clinical signs and medications recorded. Research sam-
ples were collected alongside clinical samples whenever possible at recruitment, 7 and 14 days or within 48 hours 
of these time points. Stool samples were collected into sterile containers and transferred to a Calex tube. Up to 
4 mls of venous blood was collected. 3 mls was transferred into EDTA anticoagulant and the remaining sample to 
a plain tube. The EDTA specimen was used to perform a full blood count by the hospital laboratory. The remain-
ing EDTA sample and the plain tube were centrifuged and the plasma and serum, respectively, removed and 
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stored at −80 °C at the Malawi Liverpool Wellcome Trust laboratory, Blantyre. Further processing and analyses 
were undertaken within the same laboratory.
Biomarkers of systemic and intestinal inflammation, gut integrity and growth. Stool samples 
were analysed for calprotectin (Bühlmann fCAL ELISA; Schönenbuch, Switzerland) as a biomarker of intesti-
nal inflammation. Faecal α1-antitrypsin (ELISA, Immunodiagnostik AG; Hamburg, Germany), plasma intes-
tinal fatty acid binding protein (IFABP; Human FABP2/I-FABP Quantikine ELISA Kit; R&D Systems, Inc.; 
Minneapolis, USA) and plasma IgG anti-endotoxin antibody concentration (EndoCab Human, ELISA; Hycult 
biotech; Uden, The Netherlands) were measured as markers of intestinal mucosal integrity. Plasma C-reactive 
protein and α1-acid glycoprotein (Quantikine ELISA, R&D Systems, Inc.; Minneapolis, USA) were measured 
as markers of acute and chronic systemic inflammation respectively31. Plasma insulin like growth factor (IGF)-1 
and IGF binding protein 3 (IGFBP3; Quantikine ELISA, R&D Systems, Inc.; Minneapolis, USA) as growth factors 
that are depressed in inflammation and SAM were also measured14,32. All analyses followed the manufacturer’s 
instructions. Normal ranges were those recommended by the manufacturers based on studies in healthy people. 
Laboratory staff was blinded to treatment allocations.
Outcomes. The primary endpoint was the change in FC during the intervention period. Secondary out-
comes were change in other biomarkers, gain in weight (g/kg/day after resolution of oedema if present), diarrhoea 
reported by caregivers and tolerance of feeds (vomiting reported by caregivers and requirement for naso-gastric 
tube feeds). Suspected sepsis was defined as clinical suspicion and the start or change in antibiotic therapy by the 
child’s clinical team. Treatment-emergent serious adverse events (SAEs), defined as events that commenced, or 
worsened, after the allocated feed had been administered, were reviewed by a senior paediatrician and reported 
to the Pharmacovigilance Pharmacist at LSTM. SAEs were reviewed by two blinded independent safety monitors 
and categorised according to Medical Dictionary for Regulatory Activities (MedDRA) Preferred term.
Participant withdrawal. Legal guardians were free to withdraw their child at any time. Participants were 
asked to provide an additional stool and blood sample on withdrawal from the study.
Sample size calculation. The geometric mean (standard deviation (SD)) for FC at recruitment in 37 mal-
nourished Kenyan children was 2.69 (0.45); (K Jones, personal communication)19. At the 5% significance level 
and with a coefficient of variation of 0.4, a total of 90 children (30 in each group) was needed to detect a 25% 
reduction in geometric mean calprotectin in each of the alternative feed arms compared with the standard arm 
with at least 81% power. We intended to recruit 120 children (40/group) to allow for deaths and dropouts.
Statistical analysis. The effects of the therapeutic feeds were assessed according to average change from 
baseline in laboratory and clinical variables. The earliest and latest stool and blood samples available during 
the 14-day intervention period were used to assess change in biomarkers. The primary endpoint was analysed 
using a generalised linear model (GLM) with treatment as predictor and baseline FC as covariate. The model 
had Gaussian distribution and identity link function. The treatment difference in the mean of the primary out-
come and its 95% CI were derived from the GLM model. Other biomarkers and clinical endpoints were analysed 
similarly with distributions and link functions determined by type of data (continuous, binary and count). For 
repeated measurement outcomes, mixed models with treatment as fixed effect, baseline measurement as covar-
iate, and subject as random effect were used to derive treatment differences and 95% CIs. The primary endpoint 
analysis was based on the intention to treat (ITT) population. Additional analysis in the ITT and per protocol 
population of the primary and secondary endpoints were also performed. Also, data were also analysed using a 
t-test to detect any differences in laboratory and clinical parameters between alternative feed and standard arms 
at baseline (up to day 3) and day 14 (±3 days). No imputation was made for the outcome or baseline variables. No 
interim analysis was conducted. Analysis was performed using SAS v9.4.
Results
Three hundred and sixty-seven children admitted with complicated SAM were screened. Of the 172 (46.9%) eligi-
ble children, 95 (55.2%) were randomly assigned to the three treatment arms (Fig. 1). Excluding study deviations, 
the number of children withdrawn by families was similar in the standard (3 children), elemental (5 children) and 
polymeric arms (3; P = 0.31). Withdrawals were mostly related to family concerns with the child being enrolled in 
a research study and refusal to remain under admission.
Baseline demographic and clinical characteristics (Table 1) and socioeconomic factors (Supplementary 
Table S2) were similar in the three arms. Mean (SD) age was 15.6 (5.7) months and most children lived in either 
an urban or peri-urban setting. Thirty-five (36.8%) children were breastfed and all but one child was receiving 
complementary feeds. Mean (SD) MUAC was 10.7 cm (1.2) and WHZ in children without oedema was −3.74 
(1.25). Stunting was common (height-for-age z score −2.94 (2.06)). Thirty-eight (40.0%) children with oedema-
tous malnutrition were older (P < 0.001) and had a greater mean MUAC (P < 0.001) than those without oedema 
(Supplementary Table S3). Thirty-four (36.2%) children positive for HIV had a lower mean MUAC than HIV 
negative children (P = 0.002; Supplementary Table S4). Children in the standard arm all received RUTF; only 6 
required some F-100 during their care.
Biomarkers. Geometric mean values for biomarkers at baseline (within 3 days of recruitment) and day 14 
(±3 days) according to intervention arm are shown in Fig. 2 and Supplementary Table S5. Change in biomarkers 
in the intervention arms versus the standard arm is shown in Table 2. At baseline, the gut, systemic inflammation 
and growth biomarkers were abnormal in most children with similar values in the intervention and standard 
arms (Fig. 2 and Supplementary Table S5).
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Mean FC was markedly elevated at baseline (mean (SD) 547 (744) μg/g stool; normal <50) and remained 
elevated at 14 days (697 (735); P = 0.31; Supplementary Table S5). Change in FC was similar in the intervention 
versus standard arms: elemental vs. standard 4.1 μg/mg stool/day (95% CI, −29.9, 38.15; P = 0.81) and polymeric 
vs. standard 10.0 (−23.96, 43.91; P = 0.56; Table 2).
Change in mucosal integrity biomarkers were generally similar in the intervention versus the standard arms. 
The exceptions were faecal α1-antitrypsin which increased significantly during treatment (P = 0.0046) and to a 
greater extent in the polymeric versus the standard arm (P = 0.0013) and IFABP which fell in the elemental com-
pared with the standard arm (P = 0.049).
Change in systemic inflammation biomarkers was also generally similar in the intervention versus the stand-
ard arms. The exception was plasma α1-acid glycoprotein which fell significantly in all children (P < 0.0001) and 
to a greater extent in the polymeric compared with the standard arm (P = 0.01).
IGF-1 and IGFBP3 levels were low at recruitment and increased significantly during treatment (P = < 0.0001 
for both) and to a similar degree in the intervention and standard arms. Tracking changes in biomarkers in indi-
vidual children did not identify subgroups of children who responded either better or worse to the interventions 
(Supplementary Fig. S1).
Children with oedema had a significantly higher mean plasma α1-acid glycoprotein at recruitment than those 
without (P = 0.024; Supplementary Table S3). HIV positive children had higher mean baseline values for FC 
(P = 0.005) and plasma C-reactive protein (P = 0.008) and lower haemoglobin (P = 0.007) than HIV negative 
children (Supplementary Table S4).
Nutritional recovery and clinical outcomes. Weight gain and change in MUAC and weight-for-length z 
score were similar in the intervention arms versus the standard arm (Table 2; Fig. 3). The number of days to reso-
lution of oedema was similar in the standard, elemental and polymeric arms (mean (SD): 2.38 (1.12); 2.42 (1.44); 
2.0 (1.12) respectively). Loose or watery stools were very common in all three arms (Supplementary Table S6). 
The alternative feeds were tolerated less well than standard feeds (mostly RUTF) with greater requirement for 
Figure 1. Flowchart. Study flow diagram of children with severe acute malnutrition assessed for eligibility and 
recruited for the study. 1Two additional children were known to have died after the 14-day study period and are 
not included in the Figure.
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nasogastric tube (NGT) feeding and caregiver reporting of vomiting. In addition, amongst those affected, vom-
iting occurred more frequently with the elemental compared with standard feeds (average difference = 2.22/
day, 95% CI = 1.08, 4.58; P = 0.031). However, reverting back to F75 was not required with the polymeric feed 
(Supplementary Table S6). The number of days with loose stools and vomiting amongst children who experienced 
these symptoms was similar in each arm.
When HIV status or oedema at recruitment were included in the GLM, there was no evidence of interaction 
between treatment arm and changes in clinical or laboratory outcomes except that plasma α1-acid glycoprotein 
fell to greater degree in children with oedema than those without (P = 0.025).
Serious adverse events and deaths. A total of 43 SAEs occurred in 25 (27.4%) children with a similar 
frequency in each arm (P = 0.5; Supplementary Table S7). The most frequent SAEs were gastroenteritis (13.7% 
children), dehydration (11.6%) and sepsis (6.3%). Gastroenteritis and dehydration in two children and an urti-
carial rash in one child were considered possibly related to the therapeutic feeds and all occurred in the standard 
arm. Seven children died (7.4%) within the 14-day study period; 5 deaths (71%) occurred in HIV positive chil-
dren and 3 (43%) in children with oedema. Another two children died on day 15 with death attributed to a SAE 
that started within the study period; both of these children were in the standard arm. The number of deaths was 
similar in each intervention arm (Supplementary Table S7).
Discussion
This study confirms previous observations that compromised gut integrity and intestinal and systemic inflam-
mation occur in complicated SAM. Despite moderate weight gain and a rise in growth factors in all three arms, 
biomarkers of intestinal pathology did not improve during 14 days treatment either with standard or the alterna-
tive therapeutic feeds. The biomarker findings are consistent with the on-going or recurrent diarrhoea in many 
children and the persistence of histological abnormalities despite treatment reported previously16. The persistence 
of the gut pathology likely contributes to the 10–30% case-fatality6,12,33–37, with even higher mortality in HIV 
positive children8,38, and also poor longer-term outcomes with mortality after hospital discharge typically around 
25%8,10.
The degree of intestinal inflammation in our children with complicated SAM based on FC concentrations are 
similar to that observed in Crohn’s disease28. Severely impaired mucosal integrity in our children was evidenced 
by marked abnormalities in three biomarkers. Levels of plasma I-FABP, reflecting enterocyte destruction39, were 
similar to those in south African children with SAM40, active Crohn’s disease41 and greater than those reported 
in adults with acute mesenteric ischemia42,43. Faecal α1-antitrypsin, a biomarker of intestinal protein loss and 
Variablea
Standard 
N = 31
Elemental 
N = 32 Polymeric N = 32 Total N = 95
Demographic variables
  Age in months (mean; SD) 16.6 (5.4) 14.8 (6.6) 15.5 (5.2) 15.6 (5.74)
  Male 14 (45.2) 15 (46.9) 17 (53.1) 46 (48.4)
Residence type
   Rural 10 (32.3) 9 (28.1) 10 (31.3) 29 (30.5)
   Urban 14 (45.2) 19 (59.4) 17 (53.1) 50 (52.6)
   Peri-urban 7 (22.6) 4 (12.5) 5 (15.6) 16 (16.8)
  Mother main caregiver 30 (96.8) 29 (90.6) 27 (84.4) 86 (90.5)
  Mother HIV positive 10 (37) 14 (43.8) 14 (43.8) 38 (40)
  Mother died 1 (3.2) 1 (3.1) 2 (6.3) 4 (4.2)
  Number of siblings alive (mean; SD) 1.87 (1.5) 1.78 (1.5) 1.13 (1.3) 1.59 (1.45)
  Number of siblings died (mean; SD) 0.19 (0.5) 0.13 (0.42) 0.41 (1.0) 0.24 (0.70)
Clinical variables
  Child HIV positive 11 (35.5) 12 (37.5) 11 (34.4)b 34 (35.8)
  Breastfed 22 (71) 20 (62.5) 20 (62.5) 62 (65.3)
  Receiving complementary feeds 31 (100) 31 (96.9) 32 (100) 94 (98.9)
Oedema
None 17 (54.8) 18 (56.3) 22 (68.8) 57 (60)
+ 4 (12.9) 3 (9.38) 3 (9.38) 10 (10.5)
++ 5 (16.1) 9 (28.1) 6 (18.8) 20 (21.1)
+++ 5 (16.1) 2 (6.25) 1 (3.13) 8 (8.42)
  Mid upper arm circumference (cms; mean; SD)c 10.3 (1.2) 10.5 (1.27) 11.3 (0.81) 10.7 (1.2)
  Weight-for-height z score (mean; SD)d −4.10 (1.34) −3.79 (1.28) −3.41 (1.13) −3.74 (1.25)
  Length-for-age z score (mean; SD) −2.80 (1.49) −3.01 (2.85) −3.00 (1.60) −2.94 (2.06)
Table 1. Baseline demographic and clinical characteristics according to intervention arm. aValues are number 
(%) unless otherwise stated; bHIV status not known for 1 child; cOnly reported for children without severe 
oedema (++, +++); dOnly reported for children without oedema.
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moderately increased in our patients, is also elevated in Crohn’s disease44. Finally, anti-endotoxin antibodies in 
plasma likely indicates translocation of gut bacteria40.
Significant systemic inflammation at recruitment was evidenced by raised CRP, platelet count and plasma 
α1-acid glycoprotein consistent with findings in inflammatory bowel disease45. Although plasma α1-acid 
Figure 2. Biomarkers according to intervention arm. Box plots show values at baseline (or up to day 3) and 
day 14 (±3 days) according to intervention group (standard: blue, elemental: red, polymeric: green). Boxplots 
summarise the median (midline), the mean (diamond marker) and interquartile ranges (upper and lower box). 
Whiskers are drawn to the nearest value within 1.5 times the IQR. Values outside of this range are shown as 
circles. Light blue shading shows normal range.
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glycoprotein, a biomarker of chronic inflammation, fell significantly during treatment, platelet counts increased 
and abnormal levels for all three biomarkers persisted in most children. In complicated SAM, systemic inflam-
mation may result from infections, including translocation of gut bacteria40, as well as intestinal inflammation12. 
The fall in plasma α1-acid glycoprotein may reflect treatment of systemic infection rather than reduced intestinal 
inflammation.
The failure of the two alternative feeds to improve intestinal pathology, systemic inflammation or clinical out-
comes contrasts markedly with their clinical efficacy in non-IgE mediated food allergy20,21 and Crohn’s disease. In 
Variable
Elemental vs Standard Polymeric vs Standard
Nb Change/day (95% CI) P value Nc Change/day (95% CI) P value
Intestinal inflammation
Faecal calprotectin (μg/g stool) 26/25 4.1 (−29.9, 38.2) 0.81 26/25 10 (−24.0, 43.9) 0.56
Intestinal integrity
Faecal α1-antitrypsin (mg/dl) 21/23 1.7 (−0.42, 3.8) 0.12 22/23 3.5 (1.4, 5.5) 0.0013
Plasma IgG anti-endotoxin antibodies (GMU/ml) 16/18 −1.8 (−11.8, 8.3) 0.72 17/18 −2.1 (−11.7, 7.5) 0.66
Plasma Intestinal fatty acid binding protein (pg/ml) 16/17 −194.3 (−387.6, −1.0) 0.05 17/17 −83.8 (−276.2, 108.5) 0.38
Systemic inflammation
Platelets (x109/L blood) 15/19 7.4 (−9.1, 23.9) 0.37 17/19 −7.1 (−23.0, 8.9) 0.38
Plasma C-reactive protein (mg/L) 16/17 −0.7 (−2.2, 0.81) 0.35 17/17 −0.04 (−1.55, 1 0.46) 0.95
Plasma α1-acid glycoprotein (μg/ml) 16/16 −15.7 (−84.8, 53.4) 0.65 17/16 −89.4 (−157.7, 21.1) 0.01
Growth Factors
Insulin-like growth factor −1 (ng/ml) 9/9 4.4 (−2.1, 10.9) 0.17 14/9 4.3 (−1.3, 9.9) 0.13
Insulin-like growth factor binding; protein 3 (ng/ml) 16/17 22.3 (−29.7, 74.4) 0.39 17/17 37.1 (−14.1, 88.3) 0.15
Clinical
Weight (g/kg/day) 30/30 1.6 (−3.6, 6.8) 0.54 31/30 2.5 (−2.1, 7.7) 0.33
MUAC (cms/day) 31/30 0.025 (−0.025, 0.07) 0.32 32/30 0.042 (−0.009, 0.09) 0.1
Weight-for-length z-score 30/30 0.22 (−0.29, 0.76) 0.39 31/30 0.19 (−0.31, 0.7) 0.45
Table 2. Change in laboratory biomarkers and clinical variables according to intervention arma. aData are 
number of children and generalised linear analysis of mean (95% CI) difference in change in variable/day 
in the alternative feed compared to standard feed. A negative value signifies a fall in the variable with the 
alternative therapeutic feed compared with standard feeds and vice versa for a positive value. Laboratory 
measurements were made in the first and last samples available and clinical measurements on recruitment and 
the last measurement available during the 14-day intervention period. bNumbers represent the data available 
for the elemental/standard treatment group. cNumbers represent the data available for the polymeric/standard 
treatment group. MUAC, mid-upper arm circumference.
Figure 3. Anthropometry according to intervention arm. Box plots show parameter at baseline (or up to day 
3) and day 14 (±3 days) according to intervention group (standard: blue, elemental: red, polymeric: green) 
and show the median (midline), the mean (diamond marker) and interquartile ranges (upper and lower box). 
Whiskers are drawn to the nearest value within 1.5 times the IQR. Values outside of this range are shown as 
circles.
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the latter, although the mechanism is unknown, exclusive enteral nutrition with either a polymeric or elemental 
formula reduces intestinal inflammation, promotes mucosal healing, down regulates pro-inflammatory cytokines 
and improves nutritional status16–19. Although we observed a greater fall in plasma α1-acid glycoprotein in the 
polymeric arm, possibly related to its content of transforming growth factor beta46, in the absence of a similar 
effect on other biomarkers of systemic inflammation and an increase in faecal α1-antitrypsin with the polymeric 
feed, the clinical relevance of this finding is unclear. The greater fall in IFABP in the elemental compared with 
the standard group was of borderline statistical significance and, in the absence of associated clinical benefits, 
is unlikely to be of clinical significance. The lack of efficacy of the elemental formula indicates that exclusion of 
dietary antigens present in either cow milk based therapeutic feeds or RUTF is not effective in improving enter-
opathy. The discrepancy between our findings with older studies of elemental formula which reported improved 
weight gain in malnourished children with diarrhoea26,27 may be due to differences in the patient population or 
the use of RUTF as standard treatment in our study.
The higher α1-acid glycoprotein at recruitment in oedematous children may reflect greater bacterial translo-
cation consistent with impaired intestinal integrity related to deficient glycosylation reported in kwashiorkor17. 
However, anti-endotoxin antibodies and other markers of gut integrity did not differ significantly according to 
presence of oedema. CRP and FC were particularly elevated in HIV positive children at recruitment, the latter 
consistent with findings in HIV infected Zambian children with SAM and persistent diarrhoea14. However, bio-
markers of mucosal integrity did not differ significantly according to HIV status. This has also been reported in 
South African children with SAM in whom plasma IFABP and also plasma 16sDNA as a marker of microbial 
translocation were similar in those with and without HIV40. The contribution of HIV to the enteropathy in com-
plicated SAM requires further study.
Our study had several limitations. We recruited only 55% of eligible children which limits the generalisability 
of our findings. Sample collection was difficult in these sick children who are already having samples collected for 
clinical purposes. This limited the number of samples available for the measurement of several of the biomarkers 
and risks a false negative result that incorrectly rejects a useful intervention. However, the findings across the 
clinical and laboratory variables did not suggest a trend towards a beneficial effect of either of the two interven-
tion feeds compared with standard feeds. In this open study, reporting of symptoms and clinical observations 
could have been biased. However, measurement of biomarkers was blinded and these findings were consistent 
with the non-blinded observations. Finally, although exclusive enteral nutrition with a polymeric formula in 
Crohn’s disease reduced systemic inflammation within 3–14 days47–49, and guidelines recommend that an alter-
native therapy should be considered if a clinical response has not occurred within 2 weeks50, it is possible that 
feeding for longer than 14 days may have improved outcomes in our cases. However, in our setting, longer periods 
of exclusive enteral nutrition would be impractical given their poorer tolerance than RUTF, greater requirement 
for NGT feeding and likely need for prolonged hospital admission to supervise feeding which also carries the risk 
of increased exposure to hospital acquired infections.
We are not aware of any previous studies of interventions for enteropathy in children with complicated SAM. 
In a previous study on the Moyo ward, a synbiotic supplement did not improve clinical outcomes51.
Our findings that neither the elemental nor polymeric feeds administered for up to 14 days resulted in any 
clear improvement in biomarkers of intestinal inflammation and integrity, systemic inflammation or clinical 
benefit in complicated SAM suggests multifactorial intestinal pathology. The enteropathy in complicated SAM 
may be a continuum of environmental enteric dysfunction (EED) that is ubiquitous in unhygienic settings13. 
Recent studies of EED have highlighted the critical importance of sub-clinical infection with enteropathogens 
in compromising mucosal integrity and causing intestinal and systemic inflammation52 and the high burden of 
gut pathogens in complicated SAM was associated with intestinal inflammation12. Targeting enteropathogens in 
complicated SAM may be required to improve the enteropathy.
Conclusions
Current WHO management fails to improve intestinal pathology in complicated SAM. Elemental and polymeric 
feeds did not have the hoped anti-inflammatory or clinical benefits and proved to be poorly tolerated. Further 
research is needed to better understand the intestinal pathology in complicated SAM to help develop interven-
tions that may address the unacceptably high case-fatality and poor long-term outcomes.
Data Availability
The datasets generated during this study will be available from the corresponding author on reasonable request.
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